Literature DB >> 11087571

Structure-activity relationships of 17alpha-derivatives of estradiol as inhibitors of steroid sulfatase.

R P Boivin1, V Luu-The, R Lachance, F Labrie, D Poirier.   

Abstract

The steroid sulfatase or steryl sulfatase is a microsomal enzyme widely distributed in human tissues that catalyzes the hydrolysis of sulfated 3-hydroxy steroids to the corresponding free active 3-hydroxy steroids. Since androgens and estrogens may be synthesized inside the cancerous cells starting from dehydroepiandrosterone sulfate (DHEAS) and estrone sulfate (E(1)S) available in blood circulation, the use of therapeutic agents that inhibit steroid sulfatase activity may be a rewarding approach to the treatment of androgeno-sensitive and estrogeno-sensitive diseases. In the present study, we report the chemical synthesis and biological evaluation of a new family of steroid sulfatase inhibitors. The inhibitors were designed by adding an alkyl, a phenyl, a benzyl, or a benzyl substituted at position 17alpha of estradiol (E(2)), a C18-steroid, and enzymatic assays were performed using the steroid sulfatase of homogenized JEG-3 cells or transfected in HEK-293 cells. We observed that a hydrophobic substituent induces powerful inhibition of steroid sulfatase while a hydrophilic one was weak. Although a hydrophobic group at the 17alpha-position increased the inhibitory activity, the steric factors contribute to the opposite effect. As exemplified by 17alpha-decyl-E(2) and 17alpha-dodecyl-E(2), a long flexible side chain prevents adequate fitting into the enzyme catalytic site, thus decreasing capacity to inhibit the steroid sulfatase activity. In the alkyl series, the best compromise between hydrophobicity and steric hindrance was obtained with the octyl group (IC(50) = 440 nM), but judicious branching of side chain could improve this further. Benzyl substituted derivatives of estradiol were better inhibitors than alkyl analogues. Among the series of 17alpha-(benzyl substituted)-E(2) derivatives studied, the 3'-bromobenzyl, 4'-tert-butylbenzyl, 4'-butylbenzyl, and 4'-benzyloxybenzyl groups provided the most potent inhibition of steroid sulfatase transformation of E(1)S into E(1) (IC(50) = 24, 28, 25, and 22 nM, respectively). As an example, the tert-butylbenzyl group increases the ability of the E(2) nucleus to inhibit the steroid sulfatase by 3000-fold, and it also inhibits similarly the steroid sulfatase transformations of both natural substrates, E(1)S and DHEAS. Interestingly, the newly reported family of steroid sulfatase inhibitors acts by a reversible mechanism of action that is different from the irreversible mechanism of the known inhibitor estrone sulfamate (EMATE).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11087571     DOI: 10.1021/jm0001166

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  5 in total

1.  A lipid-modified estrogen derivative that treats breast cancer independent of estrogen receptor expression through simultaneous induction of autophagy and apoptosis.

Authors:  Sutapa Sinha; Sayantani Roy; Bathula Surendar Reddy; Krishnendu Pal; Godeshala Sudhakar; Seethalakshmi Iyer; Shamit Dutta; Enfeng Wang; Pawan Kumar Vohra; Karnati Rammohan Roy; Pallu Reddanna; Debabrata Mukhopadhyay; Rajkumar Banerjee
Journal:  Mol Cancer Res       Date:  2011-02-02       Impact factor: 5.852

2.  C-3- and C-4-Substituted Bicyclic Coumarin Sulfamates as Potent Steroid Sulfatase Inhibitors.

Authors:  Dharshini Ganeshapillai; L W Lawrence Woo; Mark P Thomas; Atul Purohit; Barry V L Potter
Journal:  ACS Omega       Date:  2018-09-06

3.  (125)I-Labelled 2-Iodoestrone-3-sulfate: synthesis, characterization and OATP mediated transport studies in hormone dependent and independent breast cancer cells.

Authors:  Nilasha Banerjee; T Robert Wu; Jason Chio; Ryan Kelly; Karin A Stephenson; John Forbes; Christine Allen; John F Valliant; Reina Bendayan
Journal:  Nucl Med Biol       Date:  2014-11-08       Impact factor: 2.408

Review 4.  Estrogen Receptor Ligands: A Review (2013-2015).

Authors:  Shabnam Farzaneh; Afshin Zarghi
Journal:  Sci Pharm       Date:  2016-04-13

Review 5.  Recent progress in the development of steroid sulphatase inhibitors - examples of the novel and most promising compounds from the last decade.

Authors:  Mateusz Daśko; Sebastian Demkowicz; Karol Biernacki; Olga Ciupak; Witold Kozak; Maciej Masłyk; Janusz Rachon
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.